- Home
- DHY vs KALA Comparison
DHY vs KALA Comparison
Compare DHY & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DHY | KALA |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.3M | 172.0M |
| IPO Year | 1998 | 2017 |
Fundamental Metrics
Financial Performance| Metric | DHY | KALA |
|---|---|---|
| Price | $1.77 | $0.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 962.1K | ★ 3.0M |
| Earning Date | 01-01-0001 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.75 | $0.12 |
| 52 Week High | $2.16 | $20.58 |
Technical Indicators
Market Signals| Indicator | DHY | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 35.07 | 26.35 |
| Support Level | N/A | N/A |
| Resistance Level | $2.13 | $0.24 |
| Average True Range (ATR) | 0.03 | 0.02 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 13.33 | 9.79 |
Price Performance
Historical ComparisonAbout DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Credit Fund is a diversified, closed-end management investment company. The Fund's principal investment objective is to generate current income. Capital appreciation is a secondary objective, pursued to the extent consistent with the Fund's primary income objective.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.